Welcome to our dedicated page for Boston Scien Cp news (Ticker: BSX), a resource for investors and traders seeking the latest updates and insights on Boston Scien Cp stock.
Boston Scientific Corporation (BSX) delivers innovative medical solutions through advanced devices for cardiovascular care, neuromodulation, and minimally invasive procedures. This news hub provides investors and healthcare professionals with timely updates on regulatory milestones, product innovations, and strategic initiatives shaping the future of patient care.
Access official press releases covering clinical trial results, FDA clearances, and financial performance alongside analysis of emerging trends in interventional therapies. Our curated collection includes updates on electrophysiology advancements, urological device developments, and global healthcare partnerships.
Key updates feature Boston Scientific's leadership in catheter-based technologies, progress in chronic pain management solutions, and expansions in diagnostic imaging capabilities. Stay informed about acquisitions, research collaborations, and quality improvement initiatives that reinforce the company's market position.
Bookmark this page for direct access to verified information about BSX's contributions to interventional cardiology and operational developments. Regularly updated to serve as your primary resource for understanding Boston Scientific's impact on modern healthcare delivery.
Boston Scientific (NYSE: BSX) has announced the election of David Habiger to its board of directors, effective immediately. Habiger brings over 30 years of business leadership experience and currently serves as president and CEO of J.D. Power. He has previously led several technology companies and is a director on the Chicago Federal Reserve Board. Boston Scientific's CEO, Mike Mahoney, welcomed Habiger, citing his experience in leading technology companies through pivotal growth periods as a valuable asset to the company's board.
Habiger's extensive background includes founding Silicon Media Partners and serving as CEO for companies like Textura, NDS Group, and Sonic Solutions. He holds an M.B.A. from The University of Chicago and a bachelor's degree in business administration from St. Norbert College. His appointment is expected to contribute to Boston Scientific's ongoing efforts to deliver transformative healthcare solutions.
Boston Scientific (NYSE: BSX) reported strong Q2 2024 results, with net sales of $4.120 billion, up 14.5% on a reported basis and 14.7% organically. GAAP EPS was $0.22, while adjusted EPS reached $0.62, exceeding guidance. The company saw significant growth across segments, with Cardiovascular up 17.8% and MedSurg up 9.0%. Regionally, U.S. sales grew 16.9%, and Emerging Markets increased 14.8%. Key developments include NMPA approval in China for the FARAPULSE™ PFA System and positive clinical trial results for various products. Boston Scientific also announced plans to acquire Silk Road Medical. The company raised its full-year 2024 guidance, projecting net sales growth of 13.5-14.5% on a reported basis and adjusted EPS of $2.38-$2.42.
Boston Scientific (NYSE: BSX) announced it will hold a webcast to discuss its Q2 2024 financial results and business highlights on July 24, 2024, at 8:00 a.m. ET.
The call will be led by CEO Mike Mahoney and CFO Dan Brennan, with a news release detailing the financial results to be issued prior to the call. Investors can access the live webcast and a replay at the company's investor relations site starting one hour after the event.
Boston Scientific (NYSE: BSX) has agreed to acquire Silk Road Medical (Nasdaq: SILK) for $27.50 per share, valuing the transaction at approximately $1.16 billion. The acquisition adds Silk Road's FDA-approved TCAR technology for stroke prevention to Boston Scientific's vascular portfolio. TCAR, a minimally invasive procedure, has shown reduced stroke risks and complications compared to traditional surgery. Silk Road Medical expects net revenue of $194-198 million in 2024, marking a 10-12% increase from the previous year. The transaction is set to close in the second half of 2024, with minimal impact on Boston Scientific's adjusted earnings per share in 2024 and 2025, and potential accretive effects thereafter.
Boston Scientific announced positive six-month results from the MODULAR ATP study of the mCRM System, which integrates the EMBLEM S-ICD and EMPOWER LP. The study met all safety and efficacy endpoints, showing a 97.5% major complication-free rate and a 98.8% communication success rate between devices. The ATP success rate was 61.3%, with no patients requesting therapy deactivation. The EMPOWER LP demonstrated stable device fixation. Findings were presented at Heart Rhythm 2024 and published in The New England Journal of Medicine. The APPRAISE ATP trial also supported the modular therapy approach, showing a small reduction in first all-cause shocks over five years in a large patient group. FDA approval is anticipated in 2025.
Boston Scientific (NYSE: BSX) has elected Dr. Cheryl Pegus to its board of directors, bringing over 25 years of clinical and business leadership experience to the company. Dr. Pegus has held various prominent positions in the healthcare industry, demonstrating a strong commitment to improving healthcare quality and accessibility. Her appointment is expected to enhance Boston Scientific's strategic growth and patient care initiatives.
Boston Scientific (NYSE: BSX) is set to participate in two upcoming investor conferences in May. The executives will engage in question-and-answer sessions at Bank of America's 2024 Health Care Conference on May 14 and at Bernstein's 40th Annual Strategic Decisions Conference on May 29. The webcasts and replays of both events will be accessible on the company's investor website.
FAQ
What is the current stock price of Boston Scien Cp (BSX)?
What is the market cap of Boston Scien Cp (BSX)?
